Comparison of effectiveness and safety of simvastatin in patients <75 versus ≥75 years of age with coronary, cerebral, or peripheral arterial disease
| Autor: | Cynthia Conroy, Jennifer G. Robinson, William J Wickemeyer |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Male
Simvastatin medicine.medical_specialty Statin Arterial disease medicine.drug_class medicine.medical_treatment Coronary Artery Disease Central nervous system disease Quality of life Risk Factors Internal medicine Humans Medicine Aged Hypolipidemic Agents Retrospective Studies Peripheral Vascular Diseases Chemotherapy business.industry Vascular disease Age Factors Middle Aged medicine.disease Survival Analysis Peripheral Surgery Treatment Outcome Emergency medicine Cardiology Female Cerebral Arterial Diseases Hydroxymethylglutaryl-CoA Reductase Inhibitors Safety Cardiology and Cardiovascular Medicine business Follow-Up Studies medicine.drug |
| Zdroj: | The American Journal of Cardiology. 90:994-995 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/s0002-9149(02)02676-0 |
| Popis: | reduction than younger persons in the statin trials, 1‐3 it is reasonable to consider very elderly patients for secondary prevention when a reasonable quality of life can be expected over the next 3 to 5 years. 4 Pending the results of ongoing studies specifically addressing the value of statin therapy in the elderly, we examined the efficacy and persistence of use of simvastatin in the secondary prevention patients aged 75 years versus those aged 75 years in the computerized database of 1 clinic in our large, private cardiology practice. ••• |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect